Arizona State Retirement System Purchases 5,628 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Arizona State Retirement System boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 21.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 32,256 shares of the company's stock after acquiring an additional 5,628 shares during the quarter. Arizona State Retirement System's holdings in Vaxcyte were worth $2,640,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in PCVX. Aigen Investment Management LP acquired a new stake in Vaxcyte during the fourth quarter valued at $371,000. Proficio Capital Partners LLC purchased a new stake in shares of Vaxcyte during the 4th quarter worth about $2,915,000. Assetmark Inc. lifted its holdings in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after buying an additional 775 shares during the last quarter. J.Safra Asset Management Corp increased its holdings in Vaxcyte by 62.9% in the fourth quarter. J.Safra Asset Management Corp now owns 1,907 shares of the company's stock worth $156,000 after buying an additional 736 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Vaxcyte by 19.0% during the fourth quarter. Victory Capital Management Inc. now owns 303,556 shares of the company's stock valued at $24,849,000 after acquiring an additional 48,516 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on PCVX. Needham & Company LLC reissued a "buy" rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday. Finally, The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday, December 20th. They set a "buy" rating and a $135.00 price target for the company. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $147.50.

Remove Ads

Insiders Place Their Bets

In other news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now owns 7,175 shares of the company's stock, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the sale, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,720,610.98. This represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 54,250 shares of company stock worth $4,550,258 in the last ninety days. Insiders own 3.10% of the company's stock.

Vaxcyte Trading Up 1.8 %

NASDAQ:PCVX traded up $1.35 during mid-day trading on Friday, hitting $74.37. 835,116 shares of the company's stock traded hands, compared to its average volume of 1,180,935. The firm has a market capitalization of $9.58 billion, a price-to-earnings ratio of -16.17 and a beta of 1.02. The firm has a 50 day moving average of $82.45 and a two-hundred day moving average of $94.29. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.